Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 5/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GRB2 | P62993 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30154872 | 1.00 | ALDH1A1 (0.38) | ALDH1A1MAPTPTGS1DPP4NOS1 | |
| SCHEMBL738238 | 0.85 | — | — | |
| SCHEMBL1534982 | 0.85 | — | — | |
| SCHEMBL2032829 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL14152640 | 0.83 | DPP4 (0.43) | ALDH1A1MAPTPTGS1DPP4SLC7A5 | |
| Hydrochloric Acid SCHEMBL27147331 | 0.83 | DPP4 (0.43) | ALDH1A1MAPTPTGS1DPP4SLC7A5 | |
| Hydrochloric Acid SCHEMBL1217456 | 0.83 | DPP4 (0.43) | ALDH1A1MAPTPTGS1DPP4SLC7A5 | |
| Trifluoroacetic Acid SCHEMBL1980571 | 0.78 | SLC7A5 (0.42) | ALDH1A1MAPTPTGS1DPP4NOS1 | |
| Trifluoroacetic Acid SCHEMBL4093984 | 0.78 | SLC7A5 (0.36) | ALDH1A1MAPTPTGS1DPP4NOS1 | |
| Trifluoroacetic Acid SCHEMBL5048203 | 0.78 | SLC7A5 (0.36) | ALDH1A1MAPTPTGS1DPP4NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| EP-1392655-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1198456-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1392655-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6645968-B2 | E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; | ABBOTT LABORATORIES | 2003-11-11 | — | — | US | disclosed |
| WO-2002062762-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1198456-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-24 | — | — | EP | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028836-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | ALDH1A1 704/4885MAPT 2939/4885PTGS1 286/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | ALDH1A1 4162/4885MAPT 4273/4885PTGS1 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.